Format

Send to

Choose Destination
Neurology. 2011 Apr 12;76(15):1310-5. doi: 10.1212/WNL.0b013e3182152881.

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab.

Author information

1
Institute of Clinical Neuroimmunology, Ludwig Maximilians University, D-81377 Munich, Germany. hannah.pellkofer@med.uni-muenchen.de

Abstract

BACKGROUND:

Neuromyelitis optica (NMO) is a severe autoimmune disease targeting optic nerves and spinal cord. The monoclonal anti-CD20 B-cell antibody rituximab is an emerging therapeutic option in NMO. However, neither long-term efficacy or safety of rituximab, nor the correlation between B-cell counts, B-cell fostering cytokines, aquaporin-4 antibodies (AQP4-ab), and disease activity in NMO, have been investigated prospectively.

METHODS:

We performed a prospective long-term cohort study of 10 patients with NMO who were treated up to 5 times with rituximab as a second-line therapy. Clinical examinations, B-cell counts, and serum concentrations of BAFF (B-cell activating factor of the TNF family; also called TNFSF13b), APRIL (a proliferation-inducing ligand; also called TNFSF13), AQP4-ab, and immunoglobulin levels were measured every 3 months.

RESULTS:

Repeated treatment with rituximab led to sustained clinical stabilization in most patients with NMO. Disease activity correlated with B-cell depletion, but not clearly with AQP4-ab or levels of APRIL. BAFF levels increased after application of rituximab and indicated persisting efficacy of the drug but did not correlate with disease activity. Overall, rituximab was well-tolerated even after up to 5 consecutive treatment courses; however, we observed several severe adverse reactions.

CONCLUSION:

Our data indicate that long-term therapy with rituximab is effective in NMO as a second-line therapy and has an acceptable safety profile. Retreatment with rituximab should be applied before reappearance of circulating B cells.

CLASSIFICATION OF EVIDENCE:

This study provides Class IV evidence that repeated doses of rituximab result in stabilization in most patients.

PMID:
21482945
DOI:
10.1212/WNL.0b013e3182152881
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center